1. Home > Latest Topics >

Question 2: Antibacterial activity of levofloxacin

20 June, 2018

Question 2
Could you comment on the role of levofloxacin with regard to its antibacterial spectrum of activity against LRTIs, and in particular its activity against the emerging presence of penicillin/macrolide-resistant S. pneumoniae (PRSP/MRSP) and other resistant RTI pathogens?


LATEST TOPICS

Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024
Managing severe infections: Practical approaches for antibiotic use, including combination therapy
05 March, 2024
Updating Traditional Approaches: Expert Insights on Addressing Urinary Tract Infections
26 February, 2024
Antibiotic resistance may be driven by diverse factors, including extreme climatic events
14 February, 2024

RELATED ARTICLES

Antimicrobial resistance in respiratory tract infections: Current trends and strategies
06 August, 2021
Observing the Development of Quinolones from the Rational Application of Antibacterial Drugs During the COVID-19 Pandemic
21 March, 2023
Community-acquired pneumonia: Insights into macrolide resistance and a review of levofloxacin use
05 July, 2021
Combination antibiotic therapy for penicillin non-susceptible Streptococcus pneumoniae
14 February, 2023
Management of macrolide resistance in respiratory tract infections: An overview
09 June, 2021